RECAB-ASA; Treatment of Recurrent Abortion With Aspirin

• Status: Completed
• Trial end date: 2016-06-01
• Target enrollment: 0
• Participant gender: Female

Summary

The aim of this study is to examine whether treatment with 75 mg aspirin daily compared with placebo could reduce the risk for a new miscarriage. The treatment starts when the pregnancy is detected on transvaginal ultrasound (around gestational week 6+) and continues to week 35/36. The study is a single center, randomized, placebo-controlled, double blind and stratified for age. 400 participants with the diagnosis idiopathic recurrent abortion are enrolled, 200 in each arm aspirin / placebo.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Göteborg University
• Collaborator: Vastra Gotaland Region
• Treatments: Aspirin

Criteria

Inclusion Criteria:

• recurrent abortion (≤ 3 consecutive abortions in first trimester)

• unknown etiology after work-up

• willingness to be randomized

Exclusion Criteria:

• previous participation in the study

• known cause of recurrent abortion, requiring specific management

• age ≥ 40

• BMI above 35

• IVF pregnancy if the reason for IVF was recurrent spontaneous abortion

• ongoing treatment with aspirin for other reason

• Sjoegren syndrome